326 related articles for article (PubMed ID: 23380344)
1. Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution.
Clancy LE; Blyth E; Simms RM; Micklethwaite KP; Ma CK; Burgess JS; Antonenas V; Shaw PJ; Gottlieb DJ
Biol Blood Marrow Transplant; 2013 May; 19(5):725-34. PubMed ID: 23380344
[TBL] [Abstract][Full Text] [Related]
2. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
3. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.
Beloki L; Ramírez N; Olavarría E; Samuel ER; Lowdell MW
Cytotherapy; 2014 Oct; 16(10):1390-408. PubMed ID: 24954783
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood.
Beloki L; Ciaurriz M; Mansilla C; Zabalza A; Perez-Valderrama E; Samuel ER; Lowdell MW; Ramirez N; Olavarria E
J Transl Med; 2015 May; 13():165. PubMed ID: 25990023
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
[TBL] [Abstract][Full Text] [Related]
7. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
[TBL] [Abstract][Full Text] [Related]
8. Immune reconstitution to cytomegalovirus following partially matched-related donor transplantation: impact of in vivo T-cell depletion and granulocyte colony-stimulating factor-primed peripheral blood/bone marrow mixed grafts.
Luo XH; Huang XJ; Li D; Liu KY; Xu LP; Liu DH
Transpl Infect Dis; 2013 Feb; 15(1):22-33. PubMed ID: 22372613
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
Peggs KS; Mackinnon S
Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
[TBL] [Abstract][Full Text] [Related]
10. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
[TBL] [Abstract][Full Text] [Related]
11. Successful isolation and expansion of CMV-reactive T cells from G-CSF mobilized donors that retain a strong cytotoxic effector function.
Samuel ER; Newton K; Mackinnon S; Lowdell MW
Br J Haematol; 2013 Jan; 160(1):87-100. PubMed ID: 23043413
[TBL] [Abstract][Full Text] [Related]
12. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
[TBL] [Abstract][Full Text] [Related]
13. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
[TBL] [Abstract][Full Text] [Related]
14. Clinical-scale isolation of 'minimally manipulated' cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease.
Odendahl M; Grigoleit GU; Bönig H; Neuenhahn M; Albrecht J; Anderl F; Germeroth L; Schmitz M; Bornhäuser M; Einsele H; Seifried E; Busch DH; Tonn T
Cytotherapy; 2014 Sep; 16(9):1245-56. PubMed ID: 25108651
[TBL] [Abstract][Full Text] [Related]
15. Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution.
Horn B; Bao L; Dunham K; Stamer M; Adler S; Cowan M; Lucas K
Pediatr Infect Dis J; 2009 Jan; 28(1):65-7. PubMed ID: 19034064
[TBL] [Abstract][Full Text] [Related]
16. Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation.
Kato R; Tamaki H; Ikegame K; Yoshihara S; Kaida K; Taniguchi K; Inoue T; Ishii S; Nakata J; Fujioka T; Eguchi R; Soma T; Okada M; Ogawa H
Ann Hematol; 2015 Oct; 94(10):1707-15. PubMed ID: 26193851
[TBL] [Abstract][Full Text] [Related]
17. [Cytomegalovirus-specific T cells immune reconstitution after human leukocyte antigen matched sibling donor allogeneic bone marrow plus peripheral blood hematopoietic stem cell transplantation].
Luo XH; Chang YJ; Huo MR; Li D; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):605-9. PubMed ID: 23134850
[TBL] [Abstract][Full Text] [Related]
18. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
19. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
[TBL] [Abstract][Full Text] [Related]
20. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group.
Koehl U; Dirkwinkel E; Koenig M; Erben S; Soerensen J; Bader P; Doerr HW; Preiser W; Weissinger E; Klingebiel T; Martin H; Lehrnbecher T
Klin Padiatr; 2008; 220(6):348-52. PubMed ID: 18949669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
